2025.07.16
FIRST PATIENT IMPLANT IN THE GLOBAL CLIN···
This announcement is made by Peijia Medical Limited (the “Company”, together with itssubsidiaries, t···
2025.05.24
OCC 2025 One-Year Follow-Up Results from···
From May 29 to June 1, 2025, the 19th Oriental Congress of Cardiology (OCC 2025) grandly commenced a···
2025.05.24
EuroPCR 2025 One-Year Follow-Up Results ···
Highlights: The pivotal clinical trial enrolled 116 symptomatic patients with severe aortic reg···
2025.05.23
EuroPCR 2025 30-Day Follow-Up Results fr···
Highlights: 1. The reported results were derived from a single-center feasibility trial and 7 p···
2025.05.23
EuroPCR 2025 One-Year Follow-Up Results ···
Highlights: The pivotal trial enrolled 130 patients (including 10 roll-in patients), all of who···
2025.04.21
ONE-YEAR FOLLOW-UP RESULTS OF THE REGIST···
On April 18, 2025, at the China Valve (Hangzhou) 2025 conference, Prof. Yan Yunfeng from Prof. Song ···
2025.04.15
REGISTRATION APPLICATION FOR TaurusTrio™···
On April 14, 2025, Peijia Medical announced that the NMPA has formally accepted the registration app···
2025.04.08
HighLife granted US FDA Breakthrough Dev···
We are thrilled to congratulate our incredible partner HighLife Medical on receiving the U···
2025.03.05
SUCCESSFULLY COMPLETION OF THE FIRST TWO···
This announcement is made by Peijia Medical Limited (the “ Company”, together with itssubsidiaries, ···
2025.02.10
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY ···
The team led by Academician Ge Junbo from Zhongshan Hospitalaffiliated with Fudan University, includ···
2024.11.28
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SU···
In November 2024, Peijia Medical successfully implanted the TaurusTrio™, a self-developedtranscathet···
2024.11.26
PCR London Valves : HighLife® TSMVR SYST···
According to the clinical results, HighLife® achieved atechnical success rate of 89%. At 1 year, the···